The link between the metabolic syndrome and cancer

International Journal of Biological Sciences

Volumn 7, Issue 7, 2011, Pages 1003-1015

  Brauna, Sandra ^a   Bitton Worms, Keren ^a   le Roith, Derek ^a  

^a Legacy Heritage Clinical Research Institute at Rambam   (Israel)

Author keywords

Cancer; Metabolic syndrome

Indexed keywords

EID: 80052767622     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.1003     Document Type: Review

References (98)

1. Zimmet PZ, Alberti KG. Introduction: Globalization and the non-communicable disease epidemic. Obesity (Silver Spring) 2006;14: 1-3
2. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009;45: 1831-8
3. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009;7: 279-88
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-weight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348: 1625-38
5. EJ NR, Yakar S. The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms; Principles of Diabetes Mellitus, 2nd ed. New York, USA: Springer. 2010: 579-99
6. Haslam DW, James WP. Obesity. Lancet 2005;366: 1197-209
7. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295: 1549-55
8. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD, Li AJ. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006;107: 1520-4
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66
10. Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep 2010;10: 93-100
11. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-53
12. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91: 542-7
13. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007;86: 556-65
14. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its com-plications. Ann Intern Med 2005;143: 199-211
15. Gallagher EJ, Fierz Y, Ferguson RD, Leroith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract 2010;16: 864-73
16. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin's lym-phoma: a meta-analysis. Int J Cancer 2007;121: 1564-70
17. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007;16: 1474-8
18. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a pro-spective cohort of US women. Cancer Causes Control 2002;13: 325-32
19. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endo-metrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2007;16: 276-80
20. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000;78: 97-105
21. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008;18: 671-7
22. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96: 1152-60
23. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT, Thune I. Metabolic and hormonal pro-files: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Bi-omarkers Prev 2005;14: 33-40
24. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Albanes D. Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res 2007;67: 5569-74
25. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008;19: 1259-66
26. Manjer J, Berglund G, Bondesson L, Garne JP, Janzon L, Lind-gren A, Malina J, Matson S. Intra-urban differences in breast cancer mortality: a study from the city of Malmo in Sweden. J Epidemiol Community Health 2000;54: 279-85
27. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159: 1160-7
28. Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev 2006;15: 2391-7
29. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Ve-rona. Diabetes Care 2003;26: 1047-51
30. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE. Type 2 diabetes and subsequent inci-dence of breast cancer in the Nurses' Health Study. Diabetes Care 2003;26: 1752-8
31. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) 2009;33: 54-66
32. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Pro-tection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389: 610-4
33. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75: 73-82
34. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75: 59-72
35. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frit-titta L, Vannelli GB, Brand R, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86: 1503-10
36. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fu-jita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insu-lin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53: 3736-40
37. LeRoith D, Werner H, Beitner-Johnson D, Roberts CTJr. Molec-ular and cellular aspects of the insulin-like growth factor I re-ceptor. Endocr Rev 1995;16: 143-63
38. Schatz JH. Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology, and Develop-ment Strategies. Curr Oncol Rep 2011; Epub.
39. Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL, Yu D. Overexpression of 14-3-3zeta in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2011; Epub.
40. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 2006;17: 305-23
41. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology 1980;107: 1176-81
42. LeRoith D. Can endogenous hyperinsulinaemia explain the increased risk of cancer development and mortality in type 2 diabetes: evidence from mouse models. Diabetes Metab Res Rev 2010;26: 599-601
43. Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 2010;77: 197-213
44. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazza-rino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Mo-linolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70: 741-51
45. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying aninsulin-like growth factor II gene disrupted by targeting. Na-ture 1990;345: 78-80
46. Liu JL, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinol-ogy 1999;140: 5178-84
47. Salmon WDJr, Daughaday WH. A hormonally controlled se-rum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49: 825-36
48. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestra-diol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001;54: 149-54
49. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004;5: 201-2
50. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010;21: 610-8
51. Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohan-raj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY, Oh Y. Identi-fication of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate can-cer. J Biol Chem 2010;285: 30233-46
52. Yakar S, Pennisi P, Kim CH, Zhao H, Toyoshima Y, Gavrilova O, LeRoith D. Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. J En-docrinol Invest 2005;28: 19-22
53. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30: 586-623
54. LeRoith D, et al. The role of insulin and insulin-like growth factors in the increased risk of cancer in diabetes. RMMJ. 2011;2(2): e0043.
55. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WGJr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18: 2893-904
56. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 2005;4: 1500-02
57. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007;26: 5966-72
58. Soliman GA. The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol 2005;16: 317-23
59. Nellist M, Burgers PC, van den Ouweland AM, Halley DJ, Luider TM. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Biochem Biophys Res Commun 2005;333: 818-26
60. Novosyadlyy R, Vijayakumar A, Lann D, Fierz Y, Kurshan N, LeRoith D. Physical and functional interaction between poly-oma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Onco-gene 2009;28: 3477-86
61. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Met-formin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010;17: 351-60
62. LeRoith D, Roberts CTJr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195: 127-37
63. Gallagher EJ, et al. The increased risk of cancer in obesity and type 2 diabetes: potential mechanisms. In: Poretsky L, ed. Prin-ciples of Diabetes Mellitus. US: Springer. 2010: 583.
64. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coro-nado-Heinsohn E, Osborne CK, Yee D. Enhancement of insu-lin-like growth factor signaling in human breast cancer: estro-gen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999;13: 787-96
65. Rose DP, et al. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 2004;5: 153-165
66. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26: 1407-33
67. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372: 425-32
68. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004;59: 267-85
69. Maffei M, Fei H, Lee GH, Dani C, Leroy P, Zhang Y, Proenca R, Negrel R, Ailhaud G, Friedman JM. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 1995;92: 6957-60
70. Toyoshima Y, Gavrilova O, Yakar S, Jou W, Pack S, Asghar Z, Wheeler MB, LeRoith D. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocri-nology 2005;146: 4024-35
71. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelo-dysplastic syndromes: proliferative and anti-apoptotic activi-ties. Blood 1999;93: 1668-76
72. Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, Nakajima N, Wada K, Takeda K, Nakagama H, Nakajima A. Leptin acts as a growth factor for colorectal tu-mours at stages subsequent to tumour initiation in murine co-lon carcinogenesis. Gut 2011; epub.
73. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibo-vich SJ. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkap-paB/HIF-1alpha activation. Cell Signal 2010;22: 1350-62
74. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270: 26746-9
75. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utiliza-tion and fatty-acid oxidation by activating AMP-activated pro-tein kinase. Nat Med 2002;8: 1288-95
76. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002;80: 696-702
77. Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, Cirillo T, Cafiero M, Natale S, Astarita C. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol 2009;134: 414-6
78. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endo-crinol Metab 2007;293: E1118-28
79. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 inde-pendent of reactive oxygen species in adipocytes. Biochem Bi-ophys Res Commun 2006;341: 549-56
80. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;290: 1084-9
81. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13: 84-9
82. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN. Pe-ripheral factors in the metabolic syndrome: the pivotal role of adiponectin. Ann N Y Acad Sci 2006;1083: 185-95
83. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009;34: 339-44
84. Poretsky. the increased risk of cancer in obesity and type 2 diabetes: potential mechanisms. Principles of Diabetes Mellitus Chapter 2010;36: 589-91
85. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148: 293-300
86. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspa-se-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101: 2476-81
87. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, Yamashita H, Nagawa H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007;98: 1120-7
88. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364: 656-65
89. Onuma M BJ, Rummel TL,. Prostate cancer cell-adipocyte in-teraction:leptin mediates androgen-independent prostate can-cer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003;278: 42660-42667
90. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadi-an population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84: 272-8
91. Plaisance I, Morandi C, Murigande C, Brink M. TNF-alpha increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3K, and MEK. Am J Physiol Endocrinol Metab 2008;294: E241-50
92. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phospho-choline. Structure 1999;7: 169-77
93. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282: 2131-5
94. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288: H2031-41
95. Festa A, D'Agostino RJr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin re-sistance atherosclerosis study. Diabetes 2002;51: 1131-7
96. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an in-dependent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51: 1596-600
97. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291: 585-90
98. Puszynski K, Bertolusso R, Lipniacki T. Crosstalk between p53 and nuclear factor-B systems: pro- and anti-apoptotic functions of NF-B. IET Syst Biol 2009;3: 356-67